RevelleCare Inc. is a Canadian telemedicine company building the country's first prescription compounded skincare platform for women in perimenopause and menopause. More than six million Canadian women are in this life stage, yet the skin changes driven by estrogen decline - collagen loss, thinning, dryness, loss of elasticity - are chronically underserved. Dermatology treats skin without addressing the hormonal cause; gynecology addresses hormones without offering skin-specific formulations. No Canadian company delivers prescription hormonal skincare directly to patients at home. RevelleCare closes that gap. Patients complete an online intake assessment, are reviewed by a licensed Canadian Nurse Practitioner, and receive their personalized prescription formulation shipped directly to their door - no clinic visit required, fully PIPEDA-compliant. Our four prescription formulations include the Estrogen Repair Cream (Estradiol 0.01% + Estriol 0.3%), Night Renewal Cream (Tretinoin 0.05% + Estriol 0.03%), Non-Hormonal Repair Cream (Niacinamide, Vitamin C, Peptides), and Intimate Estriol Cream (Estriol 0.5%). Priced at $115–$195 CAD per three-month supply, blended annual revenue per patient is CAD $650. We launch September 2026 in Ontario and BC, with national expansion in 2027. Traction to date includes Dr. M. Joanne Lemieux (University of Alberta) as Scientific Advisory Board Chair and a growing community of prospective patients through The Collective. RevelleCare is raising CAD $1.4M on a SAFE at a $6.0M valuation cap to complete our telemedicine platform, acquire our first 600 patients, and reach the 2,000-5,000 patient Series A milestone. Founded by Michèle Lunney (B.Comm, Dalhousie University; Lean Six Sigma Black Belt).